Diabetes Drug Found No Better Than Placebo at Treating NAFLD

But randomized, double-blind clinical trial suggests better way to conduct future trials —

A diabetes medication described in some studies as an effective treatment for nonalcoholic fatty liver disease (NAFLD) works no better than a placebo, report researchers at University of California San Diego School of Medicine, after conducting the first randomized, double-blind, controlled clinical trial of sitagliptin, an oral antihyperglycemic marketed by Merck & Co. under the name Januvia.

Writing in the Journal of Hepatology, a multidisciplinary team headed by study senior author Rohit Loomba, MD, professor of medicine in the Division of Gastroenterology and director of the NAFLD Translational Research Unit at UC San Diego School of Medicine … Read the full story from the UC San Diego Newsroom

Study Shows Ozanimod as Effective in Treating Ulcerative Colitis

Researchers at University of California San Diego School of Medicine have shown that ozanimod (RPC1063), a novel drug molecule, is moderately effective in the treatment of ulcerative colitis. Results of the Phase II clinical trial will appear in the May 5 issue of the New England Journal of Medicine.

“This new class of immunotherapy drug traps white blood cells in the lymph nodes to prevent their escape into the gut where they cause inflammation,” said William J. Sandborn, MD … Read the Full Story from the UC San Diego Newsroom


Dr. William Sandborn

Dr. William Sandborn

William Sandborn, MD, is Professor of Medicine and Chief of the Division of Gastroenterology and Hepatology at UC San Diego.

Read the article abstract in the New England Journal of Medicine.

Study Shows Certain Gastrointestinal Tumors Associated with Higher Mortality

Researchers at University of California, San Diego School of Medicine have determined that certain gastrointestinal stromal tumors (GISTs) are more deadly than previously reported in medical literature. Findings are published online in the Journal of Gastrointestinal Surgery. … Read the Full Story from the UC San Diego Newsroom


Paul Fanta, MD, MS

Paul Fanta, MD, MS

Paul T. Fanta, MD, Health Sciences Associate Clinical Professor of Medicine in the Division of Hematology-Oncology, is a study coauthor.

Novel 3D Imaging Offers New Tool for Identifying Advanced Fibrosis in Liver

UC San Diego School of Medicine NAFLD Research Center finds MRE imaging provides highly accurate, less invasive method —

Nonalcoholic fatty liver disease, or NAFLD, comprises a group of liver disorders whose prevalence is widespread and rising. It’s estimated that at least one-third of Americans have NAFLD; among obese persons, the figure is 50 percent. … Read the Full Story from the UC San Diego Newsroom


Rohit Loomba, MD, MHSc

Rohit Loomba, MD, MHSc

Rohit Loomba, MD, MHSc, Director of the NAFLD Research Center, is first author of the study report in The American Journal of Gastroenterology.

Dr. Loomba is Professor of Medicine in the Division of Gastroenterology, Department of Medicine; and Adjunct Professor in the Division of Epidemiology, Department of Family and Preventive Medicine.

New UC San Diego Center Will Focus on Heart Health Among Latinas

Researchers at the University of California, San Diego School of Medicine have launched a new four-year, $3.7 million multidisciplinary research center to investigate the relationship between sedentary behavior and cardiovascular risk factors in Latinas, who have a disproportionately higher chance of developing heart disease than the general population.

The study is part of a new Strategically Focused Research Network created and funded by the American Heart Association (AHA). … Read the Full Story from the UC San Diego Newsroom


Dorothy Sears, PhD

Dorothy Sears, PhD

Within the multidisciplinary research center, Dorothy Sears, PhD, Associate Professor of Medicine in the Division of Endocrinology & Metabolism, will conduct studies to find and characterize biomarkers of cardiovascular disease risk associated with sedentary behavior.

Short Overnight Fasting Linked to Increased Risk of Breast Cancer Recurrence

Researchers suggest increasing duration of nightly fasting may improve prognosis —

In patients with breast cancer, a short overnight fast of less than 13 hours was associated with a statistically significant, 36 percent higher risk of breast cancer recurrence and a non-significant, 21 percent higher probability of death from the disease compared to patients who fasted 13 or more hours per night, report University of California, San Diego School of Medicine researchers.

The study, publishing online in the Journal of the American Medical Association Oncology on March 31 … Read the Full Story from the UC San Diego Newsroom

Remote Italian Village Could Harbor Secrets of Healthy Aging

Researchers will examine 300 Italian residents, all over 100 years old —

The average life expectancy in the United States is approximately 78 years old. Americans live longer, with better diets and improved health care, than ever before, but only 0.02 percent will hit the century mark.

To understand how people can live longer throughout the world, researchers at University of California, San Diego School of Medicine have teamed up with colleagues at University of Rome La Sapienza to study a group of 300 citizens, all over 100 years old, living in a remote Italian village nestled between the ocean and mountains on the country’s coast.

“We are the first group of researchers to be given permission to study this population in Acciaroli, Italy,” said Alan Maisel, MD … Read the Full Story from the UC San Diego Newsroom

Altman Clinical and Translational Research Building Makes Its Debut

New structure will be campus hub for advancing basic science to clinical applications —

Rising above Interstate 5 on the east campus of UC San Diego, the Altman Clinical and Translational Research Institute Building (ACTRI) officially opened its doors Friday in a ribbon-cutting ceremony under blue skies.

The new seven-story building of steel, glass and grooved concrete is home to the Clinical and Translational Research Institute (CTRI) at UC San Diego, established in 2010 as part of a national consortium of 60 medical research institutions created to energize bench-to-bedside efforts. … Read the Full Story from the UC San Diego Newsroom

Altman Clinical and Translational Research Institute Building Opens March 4

Stunning structure will house array of scientists and centers dedicated to speeding basic research into new treatments and therapies —

Rising above Interstate 5 on the east campus of University of California, San Diego, the Altman Clinical and Translational Research Institute Building (ACTRI), a five-sided polygon of glass, steel and grooved concrete, officially opens its doors March 4 in a ribbon-cutting ceremony.

“The building is an architectural marvel, but more important is what it represents and the work that will go on inside,” said UC San Diego Chancellor Pradeep K. Khosla. … Read the Full Story from the UC San Diego Newsroom


Dr. Gary Firestein

Dr. Gary Firestein

The director of the Clinical and Translational Research Institute at UC San Diego is Gary S. Firestein, MD, Professor of Medicine and Dean and Associate Vice Chancellor of Translational Medicine at UC San Diego.

CTRI opened in 2010 as a part of the national Clinical and Translational Science Award consortium through a five-year, $37.2 million grant from the National Center for Advancing Translational Science of the National Institutes of Health. CTRI received a $52 million renewal grant last year.

More about the activities of the CTRI

 

Predictive Proteins: Elevated Levels Trigger Metastatic Progression of Cancer Cells

New biomarker may offer more precise and accurate prognoses of disease —

Researchers at University of California, San Diego School of Medicine and Moores Cancer Center, with colleagues in Spain and Germany, have unraveled how elevated levels of particular proteins in cancer cells trigger hyperactivity in other proteins, fueling the growth and spread of a variety of cancers. … Read the Full Story from the UC San Diego Newsroom


Dr. Pradipta GhoshDr. Pradipta Ghosh is senior author of the study report, which appears in the February 26 online publication of Scientific Reports.

Pradipta Ghosh, MD, is Associate Professor of Medicine in the Division of Gastroenterology.

Read Study Report (Full Text; Open Access)